Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics, Inc. (BDTX)
:BDTX
BDTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $3.99
Previous CloseN/A
Volume170.82K
Average Volume (3M)927.08K
Market Cap
$211.80M
Enterprise Value$18.80M
Total Cash (Recent Filing)$29.99M
Total Debt (Recent Filing)$16.97M
Price to Earnings (P/E)15.7
Beta2.25
Next Earnings
Nov 10, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding56,935,280
10 Day Avg. Volume1,100,491
30 Day Avg. Volume927,081
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.27
Enterprise Value/Gross Profit0.27
Enterprise Value/Ebitda3.79
Forecast
1Y Price Target
$8.75Price Target Upside135.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBDTX-1535 shows clear evidence of activity post-osimertinib, which could translate favorably to the 1L setting, particularly in patients with non-classical mutations where osimertinib is less active.
Financial PerformanceBlack Diamond reported a net loss of $0.19 per share, which was better than the prior estimated net loss of $0.33 per share.
Market OpportunityNon-classical EGFRm NSCLC has recent epidemiology data suggesting a $1 billion market opportunity, indicating a worthwhile investment opportunity with an unmet need.
Bears Say
Investor SentimentInvestors may judge the previous silevertinib data as having decent, but not exciting activity, and the lack of follow-up to prove durability could make it difficult to interpret silevertinib's potential efficacy.
Product Launch DelayThe initial U.S. launch of silevertinib (BDTX-1535) has been moved to 2028 from the prior 2026.
Black Diamond Therapeutics News
BDTX FAQ
What was Black Diamond Therapeutics, Inc.’s price range in the past 12 months?
Black Diamond Therapeutics, Inc. lowest stock price was $1.20 and its highest was $3.99 in the past 12 months.
What is Black Diamond Therapeutics, Inc.’s market cap?
Black Diamond Therapeutics, Inc.’s market cap is $211.80M.
When is Black Diamond Therapeutics, Inc.’s upcoming earnings report date?
Black Diamond Therapeutics, Inc.’s upcoming earnings report date is Nov 10, 2025 which is in 38 days.
How were Black Diamond Therapeutics, Inc.’s earnings last quarter?
Black Diamond Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.248 by $0.058.
Is Black Diamond Therapeutics, Inc. overvalued?
According to Wall Street analysts Black Diamond Therapeutics, Inc.’s price is currently Undervalued.
Does Black Diamond Therapeutics, Inc. pay dividends?
Black Diamond Therapeutics, Inc. does not currently pay dividends.
What is Black Diamond Therapeutics, Inc.’s EPS estimate?
Black Diamond Therapeutics, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Black Diamond Therapeutics, Inc. have?
Black Diamond Therapeutics, Inc. has 56,935,280 shares outstanding.
What happened to Black Diamond Therapeutics, Inc.’s price movement after its last earnings report?
Black Diamond Therapeutics, Inc. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.248. Following the earnings report the stock price went down -15.242%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BDTX
Black Diamond Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (135.22% Upside)
$8.75 (135.22% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 72.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.79%
12-Months-Change
Fundamentals
Return on Equity
11.85%
Trailing 12-Months
Asset Growth
10.93%
Trailing 12-Months
Company Description
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics (BDTX) is a biotechnology company dedicated to the discovery and development of precision medicines for genetically defined cancers. The company focuses on creating innovative therapies that target oncogenic mutations, including previously undruggable mutations, using its proprietary Mutation-Allostery-Pharmacology (MAP) platform. Black Diamond Therapeutics is at the forefront of cancer treatment innovation, aiming to provide more effective and personalized treatment options for patients.
BDTX Stock 12 Month Forecast
Average Price Target
$8.75
▲(135.22% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Galectin Therapeutics
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Instil Bio
―
Ownership Overview
13.84% Insiders
17.19% Mutual Funds
49.98% Other Institutional Investors
14.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---